St. Jude Researchers Discover Mitochondrial Metabolic Switch That Disables Immune Gatekeepers Within Pancreatic and Other Tumors

St. Jude scientists discover that tumors disable immune cells by draining their energy, but restoring mitochondrial function can stop tumor growth.

By: AXL Media

Published: Apr 3, 2026, 7:00 AM EDT

Source: Information for this report was sourced from St. Jude Children's Research Hospital

The Metabolic Disablement of Immune Gatekeeper Cells

New research from St. Jude Children’s Research Hospital has revealed the precise mechanism by which tumors neutralize dendritic cells, the specialized immune units responsible for alerting the body to the presence of cancer. These cells function as gatekeepers that activate cytotoxic immune cells to seek out and destroy malignant growth. However, within the nutrient-sparse and chemically hostile tumor microenvironment, these dendritic cells undergo a progressive loss of mitochondrial activity. According to the study published in Science, this loss of energy-producing capacity essentially paralyzes the dendritic cells, preventing them from forming an effective anticancer immune response and allowing the tumor to grow unchecked by the body's natural defenses.

Identifying the OPA1 and NRF1 Signaling Axis

The research team, led by Hongbo Chi, identified a specific communication circuit between the mitochondria and the cell nucleus that is dismantled by the presence of a tumor. This signaling axis is composed of two critical proteins, OPA1 and NRF1, which are significantly downregulated as a cancer progresses. Within the tumor microenvironment, the suppression of these proteins acts as a metabolic "emergency switch," signaling to the dendritic cell that it is in a state of energy crisis. In response, the cell shuts down its nonessential functions, including the vital task of immunogenic activation. This discovery characterizes how tumors directly reprogram the internal metabolism of immune cells to benefit their own survival.

Restoring Antitumor Immunity Through Mitochondrial Boosting

To test whether this process could be reversed, the investigators introduced dendritic cells with artificially enhanced mitochondrial activity into tumors in preclinical mouse models. The results were immediate and transformative: the high-energy dendritic cells successfully restored immunogenic activity and improved the body's control over the tumor. Hongbo Chi, chair of the St. Jude Department of Immunology, noted that by enhancing mitochondrial function, the team could rescue the immune system's ability to recognize and attack the malignancy. This proof-of-concept suggests that the internal "battery" of an immune cell is just as important as its genetic programming when navigating the difficult terrain of a tumor.